Investigational Drug Information for Sapanisertib
✉ Email this page to a colleague
What is the development status for investigational drug Sapanisertib?
Sapanisertib is an investigational drug.
There have been 24 clinical trials for Sapanisertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 12th 2015.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., and M.D. Anderson Cancer Center.
There are ninety-six US patents protecting this investigational drug and zero international patents.
Summary for Sapanisertib
| US Patents | 96 |
| International Patents | 1,034 |
| US Patent Applications | 451 |
| WIPO Patent Applications | 283 |
| Japanese Patent Applications | 82 |
| Clinical Trial Progress | Phase 2 (2015-08-12) |
| Vendors | 62 |
Recent Clinical Trials for Sapanisertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | Calithera Biosciences, Inc | Phase 2 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
Clinical Trial Summary for Sapanisertib
Top disease conditions for Sapanisertib
Top clinical trial sponsors for Sapanisertib
US Patents for Sapanisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Sapanisertib | ⤷ Sign Up | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Sign Up |
| Sapanisertib | ⤷ Sign Up | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Sign Up |
| Sapanisertib | ⤷ Sign Up | Method of targeting glycoproteins to treat cancer | Board of Regents of the University of Nebraska (Lincoln, NE) | ⤷ Sign Up |
| Sapanisertib | ⤷ Sign Up | Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Sign Up |
| Sapanisertib | ⤷ Sign Up | Heterocyclic estrogen receptor modulators and uses thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Sapanisertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Sapanisertib | Australia | AU2014348657 | 2033-11-13 | ⤷ Sign Up |
| Sapanisertib | Australia | AU2017245411 | 2033-11-13 | ⤷ Sign Up |
| Sapanisertib | Australia | AU2019246853 | 2033-11-13 | ⤷ Sign Up |
| Sapanisertib | Brazil | BR112016010716 | 2033-11-13 | ⤷ Sign Up |
| Sapanisertib | Canada | CA2929181 | 2033-11-13 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
